191 related articles for article (PubMed ID: 28097652)
21. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
22. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE; Shi Y; Patel RH; Chen Z; Shah AP; Srivastava RK; Whitlock RS; Ibarra AM; Larson SR; Sarabia SF; Badachhape A; Starosolski Z; Ghaghada KB; Sumazin P; Annis DA; López-Terrada D; Vasudevan SA
Sci Rep; 2021 Feb; 11(1):2967. PubMed ID: 33536467
[TBL] [Abstract][Full Text] [Related]
23. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.
Migliorini D; Lazzerini Denchi E; Danovi D; Jochemsen A; Capillo M; Gobbi A; Helin K; Pelicci PG; Marine JC
Mol Cell Biol; 2002 Aug; 22(15):5527-38. PubMed ID: 12101245
[TBL] [Abstract][Full Text] [Related]
24. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.
Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
[TBL] [Abstract][Full Text] [Related]
25. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
26. MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers.
Liu J; Yang J; Pan Q; Wang X; Wang X; Chen H; Zheng X; Huang Q
Eur J Med Res; 2024 Jan; 29(1):79. PubMed ID: 38281029
[TBL] [Abstract][Full Text] [Related]
27. Puzzling over MDM4-p53 network.
Mancini F; Di Conza G; Monti O; Macchiarulo A; Pellicciari R; Pontecorvi A; Moretti F
Int J Biochem Cell Biol; 2010 Jul; 42(7):1080-3. PubMed ID: 20417304
[TBL] [Abstract][Full Text] [Related]
28. MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis.
Xu N; Wang Y; Li D; Chen G; Sun R; Zhu R; Sun S; Liu H; Yang G; Dong T
Biochem Biophys Res Commun; 2010 Oct; 401(3):417-21. PubMed ID: 20863813
[TBL] [Abstract][Full Text] [Related]
29. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.
Xie X; Lozano G; Siddik ZH
Oncogene; 2016 Sep; 35(36):4798-806. PubMed ID: 26876197
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of p53: from peptides to small molecules.
Brown CJ; Cheok CF; Verma CS; Lane DP
Trends Pharmacol Sci; 2011 Jan; 32(1):53-62. PubMed ID: 21145600
[TBL] [Abstract][Full Text] [Related]
32. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
[TBL] [Abstract][Full Text] [Related]
33. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
34. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
35. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
[TBL] [Abstract][Full Text] [Related]
36. MDM4 expression in fibrolamellar hepatocellular carcinoma.
Karki A; Putra J; Kim SS; Laquaglia MJ; Perez-Atayde AR; Sadri-Vakili G; Vakili K
Oncol Rep; 2019 Oct; 42(4):1487-1496. PubMed ID: 31322272
[TBL] [Abstract][Full Text] [Related]
37. MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability.
Mancini F; Teveroni E; Di Conza G; Monteleone V; Arisi I; Pellegrino M; Buttarelli M; Pieroni L; D'Onofrio M; Urbani A; Pontecorvi A; Mazzone M; Moretti F
Mol Cancer; 2017 Mar; 16(1):55. PubMed ID: 28270148
[TBL] [Abstract][Full Text] [Related]
38. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F
Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193
[TBL] [Abstract][Full Text] [Related]
39. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Liu T; Zhang H; Yi S; Gu L; Zhou M
Mol Oncol; 2019 May; 13(5):1047-1058. PubMed ID: 30672125
[TBL] [Abstract][Full Text] [Related]
40. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Gerhart SV; Kellner WA; Thompson C; Pappalardi MB; Zhang XP; Montes de Oca R; Penebre E; Duncan K; Boriack-Sjodin A; Le B; Majer C; McCabe MT; Carpenter C; Johnson N; Kruger RG; Barbash O
Sci Rep; 2018 Jun; 8(1):9711. PubMed ID: 29946150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]